Afamitresgene Autoleucel, also known as Afami-cel or ADP-A2M4, is a novel TCR-T cell immunotherapy that has produced durable and promising results in patients with advanced synovial sarcoma or mucinous/round cell liposarcoma
Medical
-
-
Medical
Pfizer's New Treatment Elranatamab Receives FDA Breakthrough Therapy Designation For Relapsed Or Refractory Multiple Myeloma
Pfizer's new treatment, Elranatamab, has received Breakthrough Therapy designation from the FDA for the treatment of patients with relapsed or refractory multiple myeloma. Data from the trial showed a patient efficacy rate of 61.0% and that once the therapy is effective, efficacy is maintained for more than six months in over 90% of patients!
-
Medical
New Strategies For Cancer Vaccines: Transforming Cancer Cells So They Can Become Cancer-Fighters Is Not Far Away!
In recent years, scientists have begun to look at "transforming" cancer cells from life-threatening bad actors to help fight cancer.
-
Bile duct cancer is a rare but highly malignant tumour that occurs in the human bile duct system and has long had a poor prognosis. Now, researchers at University College London and University College London Hospitals, in an international multi-centre trial, have identified potentially good treatments that may radically improve the lives of some patients with bile duct cancer.
-
Although immortality is still only a myth in the mirror, living a long and healthy life is a goal that most people seem to be able to achieve.
-
DZD1516 is a reversible, selective HER2-targeting agent with full blood-brain barrier penetration. It has demonstrated good therapeutic response in phase I studies in patients with metastatic HER2-positive breast cancer, including breast cancer patients with central nervous system metastases.
-
Medical
Cancer Cells Are So Cunning They Use 'Self-Evolution' To Resist Treatment! New Research Has Found The Answer
A recent study led by the University of Texas Southwestern Medical Center on prostate cancer shows that by stopping the "transformation" of cancer cells in prostate cancer, new treatments are expected to overcome drug resistance.
-
The European Union has approved the marketing of the new treatment Opdualag for the treatment of melanoma patients. New data demonstrates that the treatment resulted in the complete disappearance of tumours in 16.3% of patients, a significant reduction in tumours in 26.8% and stable disease without further progression in 18.2% of patients, giving an efficiency rate of 61.3%.
-
Alveolar rhabdomyosarcoma is a rare but very deadly childhood tumour, and for more than 40 years there have been no new advances in the treatment of this disease. Recently, a study led by Professor Anton Henssen of the Charité University of Berlin has identified a promising new treatment for the disease.
-
Medical
Genetic Modification Of Immune Cells To Make Them Tireless, Cold-Blooded "Cancer Cell Killers"!
A cutting-edge study from the University of California, San Francisco, recently showed that researchers have been able to make immune cells, which already recognize cancer cells, more powerful and durable through CRISPR gene editing tools, promising to become tireless, cold-blooded "cancer killers"!